Benefits
Mitophagy induction (distinguishing mechanism)
Urolithin A is one of the most potent natural mitophagy inducers identified — supporting cellular cleanup of damaged mitochondria. Mechanism distinguishes it from typical antioxidants or mitochondrial supplements; mitophagy is a more fundamental cellular renewal process.
Mitochondrial function in older adults
Clinical trials in middle-aged and older adults show urolithin A supplementation improves mitochondrial gene expression and biomarkers of mitochondrial function. Effect sizes are modest but mechanistically meaningful for aging applications.
Muscle strength and endurance preservation
Trials in older adults show urolithin A supplementation may preserve muscle strength and endurance during aging. Effects build over 4+ months of supplementation. Particularly relevant for sarcopenia (age-related muscle loss) where mitochondrial dysfunction contributes.
Exercise performance and recovery (emerging)
Emerging trials in active populations suggest urolithin A may support exercise capacity and recovery through mitochondrial function improvements. Less robust than the aging applications but mechanistically consistent.
Skin health and aging applications
Emerging research targets urolithin A for skin aging applications through mitochondrial support in skin cells. Promising preliminary evidence; not yet definitively established as a skin health intervention.
Individual gut microbiome variation
Only 30-40% of people are 'high urolithin producers' from dietary ellagitannins (pomegranates, walnuts, raspberries). The other 60-70% won't generate meaningful urolithin A from food sources. Direct supplementation bypasses this individual variation — a key practical advantage.
Manufacturing complexity and cost
Urolithin A is a complex molecule that's expensive to manufacture at supplement-grade purity. Mitopure® (Amazentis) is essentially the only commercial source with reliable manufacturing. Cost is significantly higher than typical supplements; product evaluation should consider this manufacturing reality.
Mechanism of action
Mitophagy activation via PINK1/Parkin pathway upregulation
Urolithin A activates mitophagy — the selective autophagy of dysfunctional mitochondria — by upregulating the PINK1/Parkin pathway that tags damaged mitochondria for degradation by autophagosomes. In aging muscle, defective mitochondria accumulate (mitochondrial dysfunction is a hallmark of aging) due to impaired mitophagy, reducing ATP production capacity and causing reactive oxygen species (ROS) accumulation. UA-induced mitophagy clears these defective mitochondria and triggers PGC-1α-mediated mitochondrial biogenesis to replace them with new, functional mitochondria — restoring the metabolic and contractile capacity that drives the strength and endurance improvements observed clinically.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Mitopure® 500 mg and 1,000 mg/day in 88 overweight middle-aged adults × 4 months. Published in Cell Reports.
88 overweight middle-aged adults. 4-month clinical trial with muscle biopsy analysis.
Urolithin A ~12% improvement in muscle strength. Clinically meaningful improvements in VO2 and 6-minute walk test. First human proof of mitophagy activation from nutritional supplement. Mitochondrial proteomic improvements confirmed. Well-tolerated at both doses.
Double-blind, placebo-controlled clinical trial of Urolithin A (1,000 mg/day) in adults aged 65–90 × 4 months. Published in JAMA Network Open.
Adults aged 65–90. 4-month clinical trial at two medical centers.
Urolithin A significantly improved muscle endurance, 6-minute walk distance, and mitochondrial gene expression vs. placebo. Both hand grip and leg muscle endurance improved. Mitophagy biomarkers confirmed. Well-tolerated across aging population.